Refractory atopic dermatitis treated with low dose cyclosporin

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 2, 2002, Pages 127-131

  Yu, Francis C ^a   Gibbon, Gary W ^a   Klaustermeyer, William B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ADULT; ANAMNESIS; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; ELECTROLYTE DISTURBANCE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; LOW DRUG DOSE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0036706776     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61927-8     Document Type: Article

References (34)

1. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-140.
2. Alibert JL. Description des Maladies de la Peau Observées a l'Hôpital St. Louis. Paris: Barrois L'ainé et Fils, 1806:413-446.
3. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988;260:42-46.
4. Novice FM, Collison DW, Kleinsmith DM, et al. Letterer-Siwe disease in adults. Cancer 1989;63:166-174.
5. Smith DL, Smith JG, Wong SW, deShazo RD. Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol 1995;95:116-123.
6. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4: 1-191.
7. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998;139(Suppl):13-16.
8. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189-198.
9. Ewing CI, Ashcroft C, Gibbs AC, et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998;138: 1022-1029.
10. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000;25:552-558.
11. Munkvad M. A comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema. Br J Dermatol 1989;121:763-766.
12. Brockow K, Grabenhorst P, Abeck, D, et al. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology 1999;199: 231-236.
13. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy 1974;32:321-330.
14. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-446.
15. Galli E, Chini L, Nardi S, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 1994;22: 18-22.
16. Leroy BP, Boden G, Lachapelle JM, et al. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. J Am Acad Dermatol 1993;28: 232-239.
17. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001;44(Suppl):S28-S38.
18. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44(Suppl): S47-S57.
19. Carucci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998;134:785-786.
20. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999;83:548-552.
21. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001;44:89-93.
22. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990;70:323-329.
23. Allen BR. A multicentre, double-blind, placebo-controlled crossover to assess the efficacy and safety of cyclosporin A in adult patients with severe refractory atopic dermatitis. In: Wolff K, editor. Cyclosporin A and the Skin: Proceedings of a Satellite Symposium to the Second Congress of the European Academy of Dermatology and Venereology. London: Royal Society of Medicine Services; 1991:29-37.
24. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993;129:422-430.
25. Munro CS, Levell JN, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994;130:376-380.
26. Zurbriggen B, Wuthrich B, Cachelin AB, et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999;198:56-60.
27. Van Joost T, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre, placebo-controlled study. Br J Dermatol 1994;130:634-640.
28. Zonneveld IM, De Rie MA, Beljaards RC, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996;135(Suppl):15-20.
29. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-58.
30. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-815.
31. Bottari V, Frezzolini A, Ruffelli M, et al. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999;54:507-512.
32. Caproni M, Salvatore E, Cardinali C, et al. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol 2000;121:324-328.
33. Kagi MK, Joller-Jemelka H, Wuthrich, B. Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis. Allergy 1999;54:57-63.
34. Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995;132:106-112.